---
schema_version: "secwatch.filing_event.v1"
accession: "0001576885-23-000058"
form_type: "8-K"
ticker: "ABOS"
cik: "0001576885"
company_name: "Acumen Pharmaceuticals, Inc."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T05:08:17.896946+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Acumen reports Q3 net loss $13M, plans Phase 2 AD trial H1 2024, secures $50M credit facility

## Summary
- Phase 2 ALTITUDE-AD trial expected to initiate H1 2024 after positive FDA feedback on study design.
- CSF biomarkers p-tau181 (p=0.049) and neurogranin (p=0.037) significantly improved at 60 mg/kg dose in Phase 1.
- Credit facility up to $50M from K2 HealthVentures; $30M drawn at closing, matures Nov 2027 or 2028 upon milestones.
- Cash and equivalents $282.7M as of Sept 30, 2023; expected to fund operations into H2 2026.
- Net loss $13.0M for Q3 2023 vs $10.7M Q3 2022; R&D spend $11.2M vs $8.3M YoY.

## SEC filing metadata
- accession: 0001576885-23-000058
- form_type: 8-K
- ticker: ABOS
- cik: 0001576885
- company_name: Acumen Pharmaceuticals, Inc.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576885/000157688523000058/0001576885-23-000058-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576885/000157688523000058/abos-20231113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001576885-23-000058
- JSON: https://secwatch.observer/filing/0001576885-23-000058.json
- Plain text: https://secwatch.observer/filing/0001576885-23-000058.txt

## Key facts
- Earnings Releases
  Acumen Pharmaceuticals, Inc. reported financial results for Q3 2023.
  - Period: Q3 2023
  - Result: reported results
  source text: On November 13, 2023, Acumen Pharmaceuticals, Inc. (the “ Company ”) reported financial results and business highlights for the quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1576885/000157688523000058/0001576885-23-000058-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.